IRVINE, Calif., Jan. 31, 2017 /PRNewswire/ -- Syneron
Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device
company, announced today the strengthening of its executive
management team with the appointment of Lisa A. Soderquist as Chief Human Resources
Officer, effective February 1, 2017.
She will report to Syneron Medical CEO, Amit Meridor. In this executive position, Ms.
Soderquist will have worldwide responsibility for the Company's
human resources function, with an emphasis on advancing the
Company's footprint in North
America, including performance management, talent
development, talent acquisition and compensation and benefits.
Mr. Meridor said: "We look forward to Lisa joining Syneron and
helping us to drive culture transformation and develop future
leaders. Having the right, engaged talent on our team will broaden
our global aesthetics-device position in support of our vision.
Lisa has the know-how and expertise to help us achieve this."
Ms. Soderquist brings more than 20 years of global human
resources experience, and most recently held senior human resources
leadership roles at Allergan plc from 2010 to 2017. Prior to
working at Allergan, Ms. Soderquist held various Head of HR
positions in Canada, Europe, Singapore, and the U.S. She holds a Bachelor's
of Science degree in Management from the University of Massachusetts, Amherst, and an
Advanced Degree in European Economics from the University of Copenhagen. Ms. Soderquist has been
an active lead volunteer and member of the Grants Committee with
the Susan G. Komen Foundation, Orange
County, CA. Ms. Soderquist will be located in
California.
Inducement Award Grants
In connection with the hiring of Ms. Soderquist, the Company has
approved the grant of 100,000 options to purchase ordinary shares
of the Company (Options) to Ms. Soderquist. The Options will vest
quarterly over a period of four years, with 25% of the shares
subject to the Options vesting on the one-year anniversary
following the first employment anniversary date. The exercise price
of the Options will be set pursuant the Company's established
practice which is the closing price of Syneron's ordinary shares on
the date following the announcement of Syneron's next quarterly
financial results (fourth quarter 2016 financial results to be
announced on February 15, 2017). The
grants to Ms. Soderquist, which will be in the form of an
employment inducement award, was approved by the Compensation
Committee of the Syneron Board of Directors as an inducement
material to Ms. Soderquist entering into employment with Syneron in
accordance with NASDAQ Listing Rule 5635(c)(4).
About Syneron Candela:
Syneron Candela is a leading global aesthetic device company
with a comprehensive product portfolio and a global distribution
footprint. The Company's technology enables physicians to
provide advanced solutions for a broad range of medical-aesthetic
applications including body contouring, hair removal, wrinkle
reduction, tattoo removal, women's intimate wellness treatments,
improving the skin's appearance through the treatment of
superficial benign vascular and pigmented lesions, and the
treatment of acne, leg veins and cellulite. The Company has a wide
portfolio of trusted, leading products including UltraShape,
VelaShape, GentleLase, VBeam Perfecta, PicoWay, CO2RE,
CO2RE Intima, Profound and elōs Plus.
Founded in 2000, the company markets, services and supports its
products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan,
and Hong Kong and distributors worldwide.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future
expectations, beliefs, goals, plans or prospects constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Further, any
statements that are not statements of historical fact (including
statements containing "believes," "anticipates," "plans,"
"expects," "may," "will," "would," "intends," "estimates" and
similar expressions) should also be considered to be
forward-looking statements.
Forward-looking statements in this press release include the
proposed equity awards to the new Chief Human Resources Officer and
Mr. Meridor's statements that the newly-hired executive will
help the Company drive culture transformation and develop future
leaders and that having the right, engaged talent will broaden the
Company's global aesthetics-device position in support of the
Company's vision. There are a number of important factors
that could cause actual results or events to differ materially from
those indicated by such forward-looking statements, including the
smooth integration of the new management team into the Company, the
continued success of the Total Body Shaping Business, the continued
improvements of the North American market, as well as those risks
set forth in Syneron Medical Ltd.'s most recent Annual Report on
Form 20-F, and the other factors described in the filings that
Syneron Medical Ltd. makes with the SEC from time to time. If
one or more of these factors materialize, or if any underlying
assumptions prove incorrect, Syneron Medical Ltd.'s actual results,
performance or achievements may vary materially from any future
results, performance or achievements expressed or implied by these
forward-looking statements.
In addition, the statements in this document reflect the
expectations and beliefs of Syneron Medical Ltd. as of the date of
this document. While Syneron Medical Ltd. may elect to update
these forward-looking statements publicly in the future, it
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Syneron Medical Ltd.'s views as of any date after the
date of this document.
Syneron, the Syneron logo, UltraShape, eMatrix and elos are
trademarks of Syneron Medical Ltd. and may be registered in certain
jurisdictions. The elos (Electro-Optical Synergy) technology is a
proprietary technology of Syneron Medical Ltd. All other names are
the property of their respective owners.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/syneron-medical-strengthens-senior-management-team-with-appointment-of-chief-human-resources-officer-300399701.html
SOURCE Syneron Medical Ltd.